PT3180329T - Triazóis como inibidores do recetor nr2b - Google Patents
Triazóis como inibidores do recetor nr2bInfo
- Publication number
- PT3180329T PT3180329T PT157777541T PT15777754T PT3180329T PT 3180329 T PT3180329 T PT 3180329T PT 157777541 T PT157777541 T PT 157777541T PT 15777754 T PT15777754 T PT 15777754T PT 3180329 T PT3180329 T PT 3180329T
- Authority
- PT
- Portugal
- Prior art keywords
- triazoles
- receptor inhibitors
- nr2b receptor
- nr2b
- inhibitors
- Prior art date
Links
- 108091006082 receptor inhibitors Proteins 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037831P | 2014-08-15 | 2014-08-15 | |
| US201562146656P | 2015-04-13 | 2015-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3180329T true PT3180329T (pt) | 2020-06-08 |
Family
ID=54266608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157777541T PT3180329T (pt) | 2014-08-15 | 2015-08-14 | Triazóis como inibidores do recetor nr2b |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9981950B2 (enExample) |
| EP (1) | EP3180329B1 (enExample) |
| JP (1) | JP6605020B2 (enExample) |
| DK (1) | DK3180329T3 (enExample) |
| ES (1) | ES2791186T3 (enExample) |
| HU (1) | HUE049277T2 (enExample) |
| PL (1) | PL3180329T3 (enExample) |
| PT (1) | PT3180329T (enExample) |
| WO (1) | WO2016025917A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3180315T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Pyrazoler |
| PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
| SI3319963T1 (sl) | 2015-07-09 | 2020-02-28 | Janssen Pharmaceutica Nv | Substituirani 4-azaindoli in njihova uporaba kot modulatorji receptorja GLUN2B |
| EP3414233A1 (en) | 2016-02-10 | 2018-12-19 | Janssen Pharmaceutica NV | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| MY199104A (en) * | 2016-12-14 | 2023-10-13 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| AU2020293584A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GluN2B receptor modulators |
| CA3142998A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) * | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌 |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| KR20070027503A (ko) | 2004-02-18 | 2007-03-09 | 아스트라제네카 아베 | 트리아졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도 |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| PE20090610A1 (es) | 2007-08-30 | 2009-06-11 | Takeda Pharmaceutical | Derivados de pirazol sustituidos |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| CA2719749A1 (en) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| WO2010016490A1 (ja) | 2008-08-05 | 2010-02-11 | 第一三共株式会社 | イミダゾピリジン－２－オン誘導体 |
| US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| MX2011003691A (es) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| US8969342B2 (en) * | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系ｃｄｋ９キナーゼ阻害薬 |
| PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
| DK3180315T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Pyrazoler |
| SI3319963T1 (sl) | 2015-07-09 | 2020-02-28 | Janssen Pharmaceutica Nv | Substituirani 4-azaindoli in njihova uporaba kot modulatorji receptorja GLUN2B |
| EP3414233A1 (en) | 2016-02-10 | 2018-12-19 | Janssen Pharmaceutica NV | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
-
2015
- 2015-08-14 PT PT157777541T patent/PT3180329T/pt unknown
- 2015-08-14 JP JP2017508504A patent/JP6605020B2/ja active Active
- 2015-08-14 HU HUE15777754A patent/HUE049277T2/hu unknown
- 2015-08-14 PL PL15777754T patent/PL3180329T3/pl unknown
- 2015-08-14 WO PCT/US2015/045412 patent/WO2016025917A1/en not_active Ceased
- 2015-08-14 DK DK15777754.1T patent/DK3180329T3/da active
- 2015-08-14 EP EP15777754.1A patent/EP3180329B1/en active Active
- 2015-08-14 ES ES15777754T patent/ES2791186T3/es active Active
- 2015-08-14 US US15/503,864 patent/US9981950B2/en active Active
-
2018
- 2018-04-27 US US15/964,794 patent/US10323021B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3180329T3 (pl) | 2020-08-24 |
| US9981950B2 (en) | 2018-05-29 |
| US20170226087A1 (en) | 2017-08-10 |
| HUE049277T2 (hu) | 2020-09-28 |
| DK3180329T3 (da) | 2020-04-06 |
| EP3180329A1 (en) | 2017-06-21 |
| US20180282305A1 (en) | 2018-10-04 |
| WO2016025917A1 (en) | 2016-02-18 |
| US10323021B2 (en) | 2019-06-18 |
| EP3180329B1 (en) | 2020-03-18 |
| ES2791186T3 (es) | 2020-11-03 |
| JP6605020B2 (ja) | 2019-11-13 |
| JP2017524019A (ja) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL251071A0 (en) | Benzyl-substituted indazoles as bub1 inhibitors | |
| IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| PL3180329T3 (pl) | Triazole jako inhibitory receptora NR2B | |
| IL246902A0 (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| IL246555A0 (en) | Indazole compounds as irak4 inhibitors | |
| GB201411344D0 (en) | Cloning | |
| AP2016009496A0 (en) | Substituted spirocydic inhibitors of autotaxin | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HUE036810T2 (hu) | Elrendezés jármû ajtajának nyitására | |
| PL3122667T3 (pl) | Jednostka podająca | |
| GB201405651D0 (en) | Delivering an action | |
| PL3204186T3 (pl) | Jednostka doprowadzająca | |
| IL250306A0 (en) | indazoles | |
| PL3122666T3 (pl) | Podający zespół | |
| PL3122664T3 (pl) | Jednostka doprowadzająca | |
| HK1237771A1 (en) | Triazoles as nr2b receptor inhibitors | |
| AU5514P (en) | FT01 Trachelospermum asiaticum | |
| GB201418154D0 (en) | Inhibitors | |
| AU2014301V (en) | SJ01 Trachelospermum asiaticum | |
| GB201405343D0 (en) | Feed unit |